Regorafenib News and Research

RSS
Bayer's regorafenib Phase 3 trial on metastatic colorectal cancer meets primary endpoint

Bayer's regorafenib Phase 3 trial on metastatic colorectal cancer meets primary endpoint

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Bayer HealthCare's regorafenib receives orphan drug status for GIST treatment

Bayer HealthCare's regorafenib receives orphan drug status for GIST treatment

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress